Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736227 | 0.80 | PARP1 (0.90) | PARP1LMNATERTHTTHPGD | |
| SCHEMBL8271792 | 0.80 | PARP1 (1.00) | PARP1LMNATERTHTTHPGD | |
| SCHEMBL4657767 | 0.79 | PARP1 (0.81) | PARP1LMNASMN1; SMN2TERTGAA | |
| SCHEMBL14028586 | 0.79 | PARP1 (0.58) | PARP1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8290025 | 0.78 | PARP1 (0.64) | PARP1TERT | |
| SCHEMBL6690254 | 0.76 | PARP1 (0.65) | PARP1LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5996699 | 0.76 | PARP1 (1.00) | PARP1LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2764280 | 0.76 | PARP1 (0.80) | PARP1 | |
| SCHEMBL7095976 | 0.75 | CHEK1 (0.55) | PARP1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9629545 | 0.73 | SMN1; SMN2 (0.65) | PARP1LMNASMN1; SMN2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2174659-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and uses thereof | Inotek Pharmaceuticals Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| US-6828319-B2 | Antiinflamamtory agents; strokes; cardiovascular disorders | INOTEK PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | CYP1B1, UGT1A1, CYP4B1 | PARP1 337/4885LMNA 1572/4885SMN1; SMN2 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.